Previous clinical studies have demonstrated that systemic administration of recombinant IL-12 (rhIL-12) causes hepatotoxicity and pulmonary edema—organs in which EVs are known to accumulate following intravenous injection. The gene discussed is SPRR2A; the disease is edema.